110 related articles for article (PubMed ID: 12834181)
1. Effect of doxercalciferol (1alpha-hydroxyvitamin D2) on PTH, bone turnover and bone mineral density in a hemodialysis patient with persistent secondary hyperparathyroidism post parathyroidectomy.
Parisi MS; Oliveri B; Somoza J; Mautalen C
Clin Nephrol; 2003 Jun; 59(6):471-4. PubMed ID: 12834181
[TBL] [Abstract][Full Text] [Related]
2. Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism.
Frazão JM; Elangovan L; Maung HM; Chesney RW; Acchiardo SR; Bower JD; Kelley BJ; Rodriguez HJ; Norris KC; Robertson JA; Levine BS; Goodman WG; Gentile D; Mazess RB; Kyllo DM; Douglass LL; Bishop CW; Coburn JW
Am J Kidney Dis; 2000 Sep; 36(3):550-61. PubMed ID: 10977787
[TBL] [Abstract][Full Text] [Related]
3. Intermittent oral 1alpha-hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients. 1alphaD2 Study Group.
Frazao JM; Chesney RW; Coburn JW
Nephrol Dial Transplant; 1998; 13 Suppl 3():68-72. PubMed ID: 9568825
[TBL] [Abstract][Full Text] [Related]
4. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4.
Coburn JW; Maung HM; Elangovan L; Germain MJ; Lindberg JS; Sprague SM; Williams ME; Bishop CW
Am J Kidney Dis; 2004 May; 43(5):877-90. PubMed ID: 15112179
[TBL] [Abstract][Full Text] [Related]
5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
6. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
[TBL] [Abstract][Full Text] [Related]
7. Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism.
Bergua C; Torregrosa JV; Fuster D; Gutierrez-Dalmau A; Oppenheimer F; Campistol JM
Transplantation; 2008 Aug; 86(3):413-7. PubMed ID: 18698244
[TBL] [Abstract][Full Text] [Related]
8. Effect of parathyroidectomy on bone mineral density in hemodialysis patients with secondary hyperparathyroidism: possible usefulness of preoperative determination of parathyroid hormone level for prediction of bone regain.
Yano S; Sugimoto T; Tsukamoto T; Yamaguchi T; Hattori T; Sekita KI; Kaji H; Hattori S; Kobayashi A; Chihara K
Horm Metab Res; 2003 Apr; 35(4):259-64. PubMed ID: 12778370
[TBL] [Abstract][Full Text] [Related]
9. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.
Wesseling-Perry K; Pereira RC; Sahney S; Gales B; Wang HJ; Elashoff R; Jüppner H; Salusky IB
Kidney Int; 2011 Jan; 79(1):112-9. PubMed ID: 20861820
[TBL] [Abstract][Full Text] [Related]
10. Association between increased serum osteoprotegerin levels and improvement in bone mineral density after parathyroidectomy in hemodialysis patients.
Zheng CM; Chu P; Wu CC; Ma WY; Hung KC; Hsu YH; Lin YF; Diang LK; Lu KC
Tohoku J Exp Med; 2012 Jan; 226(1):19-27. PubMed ID: 22156488
[TBL] [Abstract][Full Text] [Related]
11. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA
Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
[TBL] [Abstract][Full Text] [Related]
12. Paricalcitol for secondary hyperparathyroidism in renal transplantation.
Trillini M; Cortinovis M; Ruggenenti P; Reyes Loaeza J; Courville K; Ferrer-Siles C; Prandini S; Gaspari F; Cannata A; Villa A; Perna A; Gotti E; Caruso MR; Martinetti D; Remuzzi G; Perico N
J Am Soc Nephrol; 2015 May; 26(5):1205-14. PubMed ID: 25194004
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison.
Maung HM; Elangovan L; Frazão JM; Bower JD; Kelley BJ; Acchiardo SR; Rodriguez HJ; Norris KC; Sigala JF; Rutkowski M; Robertson JA; Goodman WG; Levine BS; Chesney RW; Mazess RB; Kyllo DM; Douglass LL; Bishop CW; Coburn JW
Am J Kidney Dis; 2001 Mar; 37(3):532-43. PubMed ID: 11228177
[TBL] [Abstract][Full Text] [Related]
14. Mortality risk among hemodialysis patients receiving different vitamin D analogs.
Tentori F; Hunt WC; Stidley CA; Rohrscheib MR; Bedrick EJ; Meyer KB; Johnson HK; Zager PG;
Kidney Int; 2006 Nov; 70(10):1858-65. PubMed ID: 17021609
[TBL] [Abstract][Full Text] [Related]
15. Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients.
Zheng CM; Wu CC; Hung CF; Liao MT; Shyu JF; Hsu YH; Lu CL; Wang YH; Zheng JQ; Chang TJ; Lin YF; Lu KC
Nutrients; 2018 Feb; 10(2):. PubMed ID: 29439405
[TBL] [Abstract][Full Text] [Related]
16. Doxercalciferol treatment of secondary hyperparathyroidism.
Dennis VC; Albertson GL
Ann Pharmacother; 2006 Nov; 40(11):1955-65. PubMed ID: 17062838
[TBL] [Abstract][Full Text] [Related]
17. Parathyroidectomy followed by kidney transplantation can improve bone mineral density in patients with secondary hyperparathyroidism.
Chou FF; Hsieh KC; Chen YT; Lee CT
Transplantation; 2008 Aug; 86(4):554-7. PubMed ID: 18724225
[TBL] [Abstract][Full Text] [Related]
18. Bone turnover markers predict changes in bone mineral density after parathyroidectomy in patients with renal hyperparathyroidism.
Lu KC; Ma WY; Yu JC; Wu CC; Chu P
Clin Endocrinol (Oxf); 2012 May; 76(5):634-42. PubMed ID: 22007930
[TBL] [Abstract][Full Text] [Related]
19. Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: an observational study.
Fernström A; Giæver J; Granroth B; Hylander B; Jensen G; Christensson A; Wikström B; Weiss L; Wrege U; Jacobson SH
Scand J Urol Nephrol; 2011 Apr; 45(3):196-205. PubMed ID: 21366390
[TBL] [Abstract][Full Text] [Related]
20. Serial changes in bone mineral density and bone turnover after correction of secondary hyperparathyroidism in a patient with pseudohypoparathyroidism type Ib.
Tollin SR; Perlmutter S; Aloia JF
J Bone Miner Res; 2000 Jul; 15(7):1412-6. PubMed ID: 10893692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]